49. Malkani, R., Zadikoff, C., Melen, O., Videnovic, A., Borushko, E., & Simuni, T. (2012). Amantadine for freezing of gait in patients with Parkinson’s disease. Clinical Neuropharmacology, 35(6), 266–268. http://doi.org/10.1097/WNF.0b013e31826e3406
50. Margis, R., Margis, R., & Rieder, C. R. (2011). Identification of blood microRNAs associated to Parkinsońs disease. Journal of biotechnology, 152(3), 96-101.
51. Martínez-Fernández, R., Gasca-Salas, C., Sánchez-Ferro, Á., & Obeso, J. Á. (2016). Actualización en la enfermedad de Parkinson. Revista Médica Clínica Las Condes, 27(3), 363-379.
52. Massano, J., & Bhatia, K. P. (2012). Clinical Approach to Parkinson’s Disease: Features, Diagnosis, and Principles of Management. Cold Spring Harbor Perspectives in Medicine, 2(6), a008870. http://doi.org/10.1101/cshperspect.a008870
53. Moisan, F., Kab, S., Mohamed, F., Canonico, M., Le Guern, M., Quintin, C., ... & Boussac-Zarebska, M. (2015). Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry, jnnp-2015.
54. Müller, T. (2015). Drugs. 75: 157. https://doi.org/10.1007/s40265-014-0343-0
55. NINDS. (2014). Parkinson's Disease: Hope Through Research. NIH. Recuperado 10 noviembre 2017 de https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Parkinsons-Disease-Hope-Through-Research
56. Nuytemans, K., Theuns, J., Cruts, M., & Van Broeckhoven, C. (2010). Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update. Human Mutation, 31(7), 763–780. http://doi.org/10.1002/humu.21277
57. Pankratz, N., & Foroud, T. (2007). Genetics of Parkinson disease. Genetics in Medicine, 9(12), 801-811.
58. Parkinson Disease - History of Parkinson's Disease. (2017). Parkinsons.org. Recuperado 10 noviembre 2017, de http://www.parkinsons.org/parkinsons-history.html
59. Parkinson's Disease Staging - Neurosurgical Service - Massachusetts General Hospital. (2017). Neurosurgery.mgh.harvard.edu. Recuperado 10 noviembre 2017, de https://neurosurgery.mgh.harvard.edu/functional/pdstages.htm
60. Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012). Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease. Movement Disorders, 27(5), 617-626.
61. Prediger, R. D. (2010). Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. Journal of Alzheimer's Disease, 20(s1), S205-S220.
62. Prodoehl, J., Planetta, P. J., Kurani, A. S., Comella, C. L., Corcos, D. M., & Vaillancourt, D. E. (2013). Brain activation differences in tremor and non-tremor dominant Parkinson’s disease. JAMA Neurology, 70(1), 100–106. http://doi.org/10.1001/jamaneurol.2013.582
63. Riederer, P., & Laux, G. (2011). MAO-inhibitors in Parkinson’s Disease. Experimental Neurobiology, 20(1), 1–17. http://doi.org/10.5607/en.2011.20.1.1
64. Rodriguez-Oroz, M. C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., & Obeso, J. A. (2009). Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. The Lancet Neurology, 8(12), 1128-1139.
65. Salsone, M., Labate, A., & Quattrone, A. (2012). Cardiac denervation precedes nigrostriatal damage in idiopathic rapid eye movement sleep behavior disorder. Movement Disorders, 27(8), 1068-1069.
66. Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., & Rocca, W. A. (2016). Time trends in the incidence of Parkinson disease. JAMA neurology, 73(8), 981-989.
67. Schulz-Schaeffer, W. J. (2010). The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta neuropathologica, 120(2), 131-143.
68. Seeman, P. (2009). "Chapter 1: Historical overview: Introduction to the dopamine receptors". The Dopamine Receptors. Springer. pp. 1–22. ISBN 1-60327-333-6
69. Seidl, S. E., Santiago, J. A., Bilyk, H., & Potashkin, J. A. (2014). The emerging role of nutrition in Parkinson’s disease. Frontiers in Aging Neuroscience, 6, 36. http://doi.org/10.3389/fnagi.2014.00036
70. Soreq, L., Salomonis, N., Bronstein, M., Greenberg, D. S., Israel, Z., Bergman, H., & Soreq, H. (2013). Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Frontiers in Molecular Neuroscience, 6, 10. http://doi.org/10.3389/fnmol.2013.00010
71. Stefanis, L. (2012). α-Synuclein in Parkinson’s Disease. Cold Spring Harbor Perspectives in Medicine, 2(2), a009399. http://doi.org/10.1101/cshperspect.a009399 Stern, M. B., Lang, A., & Poewe, W. (2012). Toward a redefinition of Parkinson's disease. Movement disorders, 27(1), 54-60.
72. Surace, M. J., & Block, M. L. (2012). Targeting Microglia-Mediated Neurotoxicity: The Potential of NOX2 Inhibitors. Cellular and Molecular Life Sciences : CMLS, 69(14), 2409–2427. http://doi.org/10.1007/s00018-012-1015-4
73. Villacé, P., Mella, R. M., & Kortazar, D. (2017). Mitochondria in the context of Parkinson’s disease. Neural Regeneration Research, 12(2), 214–215. http://doi.org/10.4103/1673-5374.200802
74. Wu, S.-L., Liscic, R. M., Kim, S., Sorbi, S., & Yang, Y.-H. (2017). Nonmotor Symptoms of Parkinson’s Disease. Parkinson’s Disease, 2017, 4382518. http://doi.org/10.1155/2017/4382518
75. Zhao, Y. J., Wee, H. L., Chan, Y. H., Seah, S. H., Au, W. L., Lau, P. N., ... & Tan, L. (2010). Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Movement Disorders, 25(6), 710-716.
12